A Randomized Controlled Trial of ACT-P Versus T4C for Community Reentry
Launched by IOWA STATE UNIVERSITY · Oct 27, 2021
Trial Information
Current as of November 07, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This trial is testing two programs to help men leave prison and stay out of trouble: ACT-P (Acceptance and Commitment Therapy for prisons) and T4C (Thinking for Change). In a randomized setup, participants are assigned by chance to receive either ACT-P or T4C in parallel groups. The main goal is to see which program more effectively reduces criminal activity after release, by looking at rearrests, new convictions, and reincarcerations over the next 3 years. The study is for adult men who are currently in prison, are considered medium or high risk of reoffending, and are eligible for cognitive therapy; men who are court-mandated to participate are not eligible.
About 400 participants are planned, enrolled by invitation, and the study is taking place at Fort Dodge Correctional Facility in Fort Dodge, Iowa. ACT-P includes five modules plus ongoing “Big Picture” sessions, focusing on values, awareness, and behavior change, while T4C focuses on changing criminal thinking through cognitive-behavioral techniques. After release, researchers will follow participants for up to 3 years to track whether they are rearrested, reconvicted, or reincarcerated. No results are available yet, and the project is expected to run through 2026.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • deemed medium or high risk according to the Iowa Risk Revised
- • eligible and appropriate for cognitive programming as determined by normal operating procedures
- Exclusion Criteria:
- • court-mandated to either program
About Iowa State University
Iowa State University (ISU) is a renowned research institution committed to advancing knowledge and improving health outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, ISU leverages its expertise in agriculture, engineering, and health sciences to conduct cutting-edge research that addresses pressing health challenges. The university's clinical trial programs are designed to uphold the highest ethical standards and regulatory compliance, fostering a safe environment for participants while contributing valuable insights to the medical community. ISU's dedication to education, research excellence, and community engagement positions it as a leader in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fort Dodge, Iowa, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials